Gabapentin Capsule
Product Images NDC 72162-1813

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-1813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A formula depicting the calculation for creatinine clearance (CLCr), incorporating age, weight, serum creatinine, and a factor adjustment for female patients. This scientific formula relates to pharmacokinetic parameters relevant to drug dosing.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin showing a cyclohexane ring attached to a central carbon connected to two groups: an amine (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, covering a 4-week dose titration and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin shows a declining pain score trend compared to placebo.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

A line graph depicting mean pain score over weeks for placebo and two daily dosages of Gabapentin (1800 mg and 2400 mg). The x-axis shows weeks from baseline to week 7, and the y-axis represents mean pain scores from 0 to 10. The graph distinguishes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Significance levels are indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot graph comparing the difference percentage by daily dose (mg) for Gabapentin 300 mg capsules, showing data points from three studies labeled as Study a, Study b, and Study c across doses from 600 mg to 1800 mg daily.*

FDA Label Image

Label (Lbl721621813)

Gabapentin Capsules, USP 300 mg oral capsules label showing NDC 72162-1813-9. The label indicates a package size of 90 capsules, repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufactured by Amneal Pharmaceuticals Pvt Ltd. Storage instructions and a warning about dizziness are also present on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.